Status:
COMPLETED
Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
2-18 years
Brief Summary
This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical compl...
Eligibility Criteria
Inclusion
- Children/adolescents with type 1 diabetes mellitus
- After the participating physician's decision has been made to initiate treatment with NovoPen Echo®, any patient who meets all the inclusion criteria and does not meet any of the exclusion criteria, is eligible to participate
- Use of insulin pen or syringes for at least 12 months
Exclusion
- Insulin pump or Insuflon® users
- Any disease or condition in children/adolescents which might interfere with the study at the individual physician's discretion
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
358 Patients enrolled
Trial Details
Trial ID
NCT01180530
Start Date
October 1 2010
End Date
March 1 2011
Last Update
February 8 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mississauga, Canada, L4W 4XI
2
Novo Nordisk Investigational Site
Espoo, Finland, FI-02600
3
Novo Nordisk Investigational Site
Kfar Saba, Israel, 44425
4
Novo Nordisk Investigational Site
Malmo, Sweden, 202 15